Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
In 2008, the Food and Drugs Administration required manufacturers of TNFalpha antagonists to strengthen their warnings about the risk of serious fungal infections in patients with rheumatoid arthritis (RA). Sinus aspergilloma occurs occasionally in RA patients and can progress to invasive Aspergillu...
Gespeichert in:
| Veröffentlicht in: | Arthritis research & therapy 2009-01, Vol.11 (6), p.R164-R164, Article R164 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | R164 |
|---|---|
| container_issue | 6 |
| container_start_page | R164 |
| container_title | Arthritis research & therapy |
| container_volume | 11 |
| creator | Leboime, Ariane Berthelot, Jean-Marie Allanore, Yannick Khalil-Kallouche, Lama Herman, Philippe Orcel, Philippe Lioté, Frédéric |
| description | In 2008, the Food and Drugs Administration required manufacturers of TNFalpha antagonists to strengthen their warnings about the risk of serious fungal infections in patients with rheumatoid arthritis (RA). Sinus aspergilloma occurs occasionally in RA patients and can progress to invasive Aspergillus disease. The purpose of this study was to describe symptomatic sinus aspergilloma in RA patients treated with TNFalpha antagonists.
Retrospective descriptive study of symptomatic cases of sinus aspergilloma in patients with RA followed in three French university hospitals. A systematic literature review was performed.
Among 550 RA patients treated with TNFalpha antagonists, six (1.1%) had symptomatic maxillary aspergilloma diagnosed by computed tomography before or during TNFalpha antagonist therapy. None had chronic neutropenia. Aspergilloma treatment was with surgery only in all six patients. In the literature, we found 20 reports of Aspergillus infection in patients with chronic inflammatory joint diseases (including 10 with RA). Only 5/20 patients were treated with TNFalpha antagonists (invasive lung aspergillosis, n = 3; intracranial aspergillosis, n = 1; and sphenoidal sinusitis, n = 1).
Otorhinolaryngological symptoms must be evaluated before starting or switching TNFalpha antagonists. Routine computed tomography of the sinuses before starting or switching TNFalpha antagonists may deserve consideration. |
| doi_str_mv | 10.1186/ar2849 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3003503</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A212816365</galeid><sourcerecordid>A212816365</sourcerecordid><originalsourceid>FETCH-LOGICAL-b578t-ce7343c397d42191522007f826296ca20c7c477a7f5f1d0e66c27cd7caff844f3</originalsourceid><addsrcrecordid>eNp9kktrFTEUxwdRbK36ESS40NXUvGaSbIRSfEHBhboO52aSmVxmkjHJCP32ptxLrxWUBPI4v_xPzqNpXhJ8SYjs30GikqtHzTnhQrY96-nj-33Hz5pnOe8xplRR_rQ5I0rKXil63uy_-bBlBHm1afTzHBdAPqA02W2BEv2AIJUp-eIz2lkXk0UxoWFLPoyobEs9BGtSzNXuwJSYWpjXCRCEAmMMPhdUJptgvX3ePHEwZ_viuF40Pz5--H79ub35-unL9dVNu-uELK2xgnFmmBIDp0SRjlKMhZO0p6o3QLERhgsBwnWODNj2vaHCDMKAc5Jzxy6a9wfdddstdjA2lASzXpNfIN3qCF4_tAQ_6TH-0gxj1mFWBdRBYOfjPwQeWkxc9KEA9e3bo_MUf242F734bOw8Q7Bxy1qwWo46SSXf_JekhArZcVHB13-B-7ilUFNYGcGlqqmp0OUBGmG22gcX689MHYNdvInBOl_vr6qoJLU7upP7u-LlZN19fATru5Y6RfTqz3SesGMPsd_8msoC</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217489826</pqid></control><display><type>article</type><title>Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><source>SpringerLink Journals - AutoHoldings</source><source>PubMed Central Open Access</source><creator>Leboime, Ariane ; Berthelot, Jean-Marie ; Allanore, Yannick ; Khalil-Kallouche, Lama ; Herman, Philippe ; Orcel, Philippe ; Lioté, Frédéric</creator><creatorcontrib>Leboime, Ariane ; Berthelot, Jean-Marie ; Allanore, Yannick ; Khalil-Kallouche, Lama ; Herman, Philippe ; Orcel, Philippe ; Lioté, Frédéric</creatorcontrib><description>In 2008, the Food and Drugs Administration required manufacturers of TNFalpha antagonists to strengthen their warnings about the risk of serious fungal infections in patients with rheumatoid arthritis (RA). Sinus aspergilloma occurs occasionally in RA patients and can progress to invasive Aspergillus disease. The purpose of this study was to describe symptomatic sinus aspergilloma in RA patients treated with TNFalpha antagonists.
Retrospective descriptive study of symptomatic cases of sinus aspergilloma in patients with RA followed in three French university hospitals. A systematic literature review was performed.
Among 550 RA patients treated with TNFalpha antagonists, six (1.1%) had symptomatic maxillary aspergilloma diagnosed by computed tomography before or during TNFalpha antagonist therapy. None had chronic neutropenia. Aspergilloma treatment was with surgery only in all six patients. In the literature, we found 20 reports of Aspergillus infection in patients with chronic inflammatory joint diseases (including 10 with RA). Only 5/20 patients were treated with TNFalpha antagonists (invasive lung aspergillosis, n = 3; intracranial aspergillosis, n = 1; and sphenoidal sinusitis, n = 1).
Otorhinolaryngological symptoms must be evaluated before starting or switching TNFalpha antagonists. Routine computed tomography of the sinuses before starting or switching TNFalpha antagonists may deserve consideration.</description><identifier>ISSN: 1478-6354</identifier><identifier>EISSN: 1478-6362</identifier><identifier>EISSN: 1478-6354</identifier><identifier>DOI: 10.1186/ar2849</identifier><identifier>PMID: 19886992</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Aged ; Antagonists (Biochemistry) ; Antibodies, Monoclonal - therapeutic use ; Antirheumatic Agents - therapeutic use ; Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - drug therapy ; Aspergillosis - complications ; Aspergillosis - surgery ; Aspergillus ; Care and treatment ; Complications and side effects ; Diagnosis ; Etanercept ; Health aspects ; Humans ; Immunoglobulin G - therapeutic use ; Infliximab ; Middle Aged ; Paranasal Sinus Diseases - complications ; Paranasal Sinus Diseases - surgery ; Patient outcomes ; Physiological aspects ; Pulmonary aspergillosis ; Receptors, Tumor Necrosis Factor - therapeutic use ; Retrospective Studies ; Rheumatoid arthritis ; Risk factors ; Tumor necrosis factor ; Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><ispartof>Arthritis research & therapy, 2009-01, Vol.11 (6), p.R164-R164, Article R164</ispartof><rights>COPYRIGHT 2009 BioMed Central Ltd.</rights><rights>Copyright National Library of Medicine - MEDLINE Abstracts 2009</rights><rights>Copyright ©2009 Leboime et al.; licensee BioMed Central Ltd. 2009 Leboime et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b578t-ce7343c397d42191522007f826296ca20c7c477a7f5f1d0e66c27cd7caff844f3</citedby><cites>FETCH-LOGICAL-b578t-ce7343c397d42191522007f826296ca20c7c477a7f5f1d0e66c27cd7caff844f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003503/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003503/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19886992$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leboime, Ariane</creatorcontrib><creatorcontrib>Berthelot, Jean-Marie</creatorcontrib><creatorcontrib>Allanore, Yannick</creatorcontrib><creatorcontrib>Khalil-Kallouche, Lama</creatorcontrib><creatorcontrib>Herman, Philippe</creatorcontrib><creatorcontrib>Orcel, Philippe</creatorcontrib><creatorcontrib>Lioté, Frédéric</creatorcontrib><title>Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy</title><title>Arthritis research & therapy</title><addtitle>Arthritis Res Ther</addtitle><description>In 2008, the Food and Drugs Administration required manufacturers of TNFalpha antagonists to strengthen their warnings about the risk of serious fungal infections in patients with rheumatoid arthritis (RA). Sinus aspergilloma occurs occasionally in RA patients and can progress to invasive Aspergillus disease. The purpose of this study was to describe symptomatic sinus aspergilloma in RA patients treated with TNFalpha antagonists.
Retrospective descriptive study of symptomatic cases of sinus aspergilloma in patients with RA followed in three French university hospitals. A systematic literature review was performed.
Among 550 RA patients treated with TNFalpha antagonists, six (1.1%) had symptomatic maxillary aspergilloma diagnosed by computed tomography before or during TNFalpha antagonist therapy. None had chronic neutropenia. Aspergilloma treatment was with surgery only in all six patients. In the literature, we found 20 reports of Aspergillus infection in patients with chronic inflammatory joint diseases (including 10 with RA). Only 5/20 patients were treated with TNFalpha antagonists (invasive lung aspergillosis, n = 3; intracranial aspergillosis, n = 1; and sphenoidal sinusitis, n = 1).
Otorhinolaryngological symptoms must be evaluated before starting or switching TNFalpha antagonists. Routine computed tomography of the sinuses before starting or switching TNFalpha antagonists may deserve consideration.</description><subject>Aged</subject><subject>Antagonists (Biochemistry)</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Aspergillosis - complications</subject><subject>Aspergillosis - surgery</subject><subject>Aspergillus</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Diagnosis</subject><subject>Etanercept</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunoglobulin G - therapeutic use</subject><subject>Infliximab</subject><subject>Middle Aged</subject><subject>Paranasal Sinus Diseases - complications</subject><subject>Paranasal Sinus Diseases - surgery</subject><subject>Patient outcomes</subject><subject>Physiological aspects</subject><subject>Pulmonary aspergillosis</subject><subject>Receptors, Tumor Necrosis Factor - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Rheumatoid arthritis</subject><subject>Risk factors</subject><subject>Tumor necrosis factor</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><issn>1478-6354</issn><issn>1478-6362</issn><issn>1478-6354</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kktrFTEUxwdRbK36ESS40NXUvGaSbIRSfEHBhboO52aSmVxmkjHJCP32ptxLrxWUBPI4v_xPzqNpXhJ8SYjs30GikqtHzTnhQrY96-nj-33Hz5pnOe8xplRR_rQ5I0rKXil63uy_-bBlBHm1afTzHBdAPqA02W2BEv2AIJUp-eIz2lkXk0UxoWFLPoyobEs9BGtSzNXuwJSYWpjXCRCEAmMMPhdUJptgvX3ePHEwZ_viuF40Pz5--H79ub35-unL9dVNu-uELK2xgnFmmBIDp0SRjlKMhZO0p6o3QLERhgsBwnWODNj2vaHCDMKAc5Jzxy6a9wfdddstdjA2lASzXpNfIN3qCF4_tAQ_6TH-0gxj1mFWBdRBYOfjPwQeWkxc9KEA9e3bo_MUf242F734bOw8Q7Bxy1qwWo46SSXf_JekhArZcVHB13-B-7ilUFNYGcGlqqmp0OUBGmG22gcX689MHYNdvInBOl_vr6qoJLU7upP7u-LlZN19fATru5Y6RfTqz3SesGMPsd_8msoC</recordid><startdate>20090101</startdate><enddate>20090101</enddate><creator>Leboime, Ariane</creator><creator>Berthelot, Jean-Marie</creator><creator>Allanore, Yannick</creator><creator>Khalil-Kallouche, Lama</creator><creator>Herman, Philippe</creator><creator>Orcel, Philippe</creator><creator>Lioté, Frédéric</creator><general>BioMed Central Ltd</general><general>National Library of Medicine - MEDLINE Abstracts</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>M7N</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090101</creationdate><title>Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy</title><author>Leboime, Ariane ; Berthelot, Jean-Marie ; Allanore, Yannick ; Khalil-Kallouche, Lama ; Herman, Philippe ; Orcel, Philippe ; Lioté, Frédéric</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b578t-ce7343c397d42191522007f826296ca20c7c477a7f5f1d0e66c27cd7caff844f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Aged</topic><topic>Antagonists (Biochemistry)</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Aspergillosis - complications</topic><topic>Aspergillosis - surgery</topic><topic>Aspergillus</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Diagnosis</topic><topic>Etanercept</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunoglobulin G - therapeutic use</topic><topic>Infliximab</topic><topic>Middle Aged</topic><topic>Paranasal Sinus Diseases - complications</topic><topic>Paranasal Sinus Diseases - surgery</topic><topic>Patient outcomes</topic><topic>Physiological aspects</topic><topic>Pulmonary aspergillosis</topic><topic>Receptors, Tumor Necrosis Factor - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Rheumatoid arthritis</topic><topic>Risk factors</topic><topic>Tumor necrosis factor</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leboime, Ariane</creatorcontrib><creatorcontrib>Berthelot, Jean-Marie</creatorcontrib><creatorcontrib>Allanore, Yannick</creatorcontrib><creatorcontrib>Khalil-Kallouche, Lama</creatorcontrib><creatorcontrib>Herman, Philippe</creatorcontrib><creatorcontrib>Orcel, Philippe</creatorcontrib><creatorcontrib>Lioté, Frédéric</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arthritis research & therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leboime, Ariane</au><au>Berthelot, Jean-Marie</au><au>Allanore, Yannick</au><au>Khalil-Kallouche, Lama</au><au>Herman, Philippe</au><au>Orcel, Philippe</au><au>Lioté, Frédéric</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy</atitle><jtitle>Arthritis research & therapy</jtitle><addtitle>Arthritis Res Ther</addtitle><date>2009-01-01</date><risdate>2009</risdate><volume>11</volume><issue>6</issue><spage>R164</spage><epage>R164</epage><pages>R164-R164</pages><artnum>R164</artnum><issn>1478-6354</issn><eissn>1478-6362</eissn><eissn>1478-6354</eissn><abstract>In 2008, the Food and Drugs Administration required manufacturers of TNFalpha antagonists to strengthen their warnings about the risk of serious fungal infections in patients with rheumatoid arthritis (RA). Sinus aspergilloma occurs occasionally in RA patients and can progress to invasive Aspergillus disease. The purpose of this study was to describe symptomatic sinus aspergilloma in RA patients treated with TNFalpha antagonists.
Retrospective descriptive study of symptomatic cases of sinus aspergilloma in patients with RA followed in three French university hospitals. A systematic literature review was performed.
Among 550 RA patients treated with TNFalpha antagonists, six (1.1%) had symptomatic maxillary aspergilloma diagnosed by computed tomography before or during TNFalpha antagonist therapy. None had chronic neutropenia. Aspergilloma treatment was with surgery only in all six patients. In the literature, we found 20 reports of Aspergillus infection in patients with chronic inflammatory joint diseases (including 10 with RA). Only 5/20 patients were treated with TNFalpha antagonists (invasive lung aspergillosis, n = 3; intracranial aspergillosis, n = 1; and sphenoidal sinusitis, n = 1).
Otorhinolaryngological symptoms must be evaluated before starting or switching TNFalpha antagonists. Routine computed tomography of the sinuses before starting or switching TNFalpha antagonists may deserve consideration.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>19886992</pmid><doi>10.1186/ar2849</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-6354 |
| ispartof | Arthritis research & therapy, 2009-01, Vol.11 (6), p.R164-R164, Article R164 |
| issn | 1478-6354 1478-6362 1478-6354 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3003503 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Springer Nature OA/Free Journals; SpringerLink Journals - AutoHoldings; PubMed Central Open Access |
| subjects | Aged Antagonists (Biochemistry) Antibodies, Monoclonal - therapeutic use Antirheumatic Agents - therapeutic use Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - drug therapy Aspergillosis - complications Aspergillosis - surgery Aspergillus Care and treatment Complications and side effects Diagnosis Etanercept Health aspects Humans Immunoglobulin G - therapeutic use Infliximab Middle Aged Paranasal Sinus Diseases - complications Paranasal Sinus Diseases - surgery Patient outcomes Physiological aspects Pulmonary aspergillosis Receptors, Tumor Necrosis Factor - therapeutic use Retrospective Studies Rheumatoid arthritis Risk factors Tumor necrosis factor Tumor Necrosis Factor-alpha - antagonists & inhibitors |
| title | Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T18%3A10%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sinus%20aspergilloma%20in%20rheumatoid%20arthritis%20before%20or%20during%20tumor%20necrosis%20factor-alpha%20antagonist%20therapy&rft.jtitle=Arthritis%20research%20&%20therapy&rft.au=Leboime,%20Ariane&rft.date=2009-01-01&rft.volume=11&rft.issue=6&rft.spage=R164&rft.epage=R164&rft.pages=R164-R164&rft.artnum=R164&rft.issn=1478-6354&rft.eissn=1478-6362&rft_id=info:doi/10.1186/ar2849&rft_dat=%3Cgale_pubme%3EA212816365%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217489826&rft_id=info:pmid/19886992&rft_galeid=A212816365&rfr_iscdi=true |